#USA #Atlanta #Clinical Trials #AI Automation #Florence Healthcare

Florence Automates Connections in Clinical Trials

Florence, a pioneering clinical trial technology company, is making waves in the medical research sector by introducing artificial intelligence (AI) tools that significantly enhance the connection between clinical study sites and sponsors. By transitioning from merely storing trial data to actively automating processes, Florence is poised to transform the landscape of clinical trials.

A New Vision for Clinical Research

In a keynote address at the Research Revolution event in Atlanta, CEO Ryan Jones shared the company's new vision: to connect and automate, rather than just collect data. For too long, clinical trial technology has built systems that caused more headaches than solutions for research teams. Jones highlighted that existing systems require researchers to handle a multitude of portals and logins, leading to frustration and inefficiency. In fact, according to Florence's 2026 State of Clinical Trial Technology Report, an alarming 64% of study sites feel overwhelmed by redundant sponsor technologies, and an astounding 95% still rely on emails to exchange crucial study documents.

Jones emphasized the need for change, stating, "We’ve built a world where humans work for the software, instead of the software working for humans." His call to action is clear: software should handle the intricate legwork of data management, allowing researchers the freedom to focus on critical decision-making.

The Growing Capacity Gap

As drug pipeline candidates proliferate at an annual growth rate of 8%, site activations lag behind at merely 4%. This discrepancy has resulted in a staggering 33% gap, exposing the urgent need for real-time solutions. Catherine Gregor, Florence’s chief clinical trial officer, pointed out the pressing necessity to reevaluate operational models to prevent unnecessary burdens, both for study sites and sponsors. Simply relying on outdated frameworks will only compound inefficiencies, making the burden of inaction increasingly untenable.

From Record Keeping to Automation

Florence has come a long way since it pioneered the electronic investigator site file (eISF) in 2015. Initially designed as a method for record-keeping, it has now evolved into an active system that connects disparate tasks typically managed in isolation by sites and sponsors. The next logical step is adopting a system of automation, where the software performs the heavy lifting.

Florence has already set this transformative process in motion with innovative solutions like Site Feasibility and DocQC, launched in September. Site Feasibility allows study sites to efficiently respond to sponsor queries by leveraging a library of their past answers, supported by AI suggestions. DocQC enhances document handling by identifying quality issues as they arise, always ensuring that a human makes the final decision.

A Network Designed for the Future

Florence's commitment to innovation is reflected in its impressive scale, with support for 88,000 study sites across 90 countries and the handling of over 44 million documents. In the past decade, Florence has played a vital role in achieving 140 regulatory approvals, including 39 drug and biologic approvals and 84 medical device approvals. These achievements underscore the company's dedication to fostering efficient clinical trials alongside advancing medical research.

The integration of AI and automation allows Florence to redefine clinical trial processes, empowering study sites to utilize systems under their control rather than navigating cumbersome sponsor portals. This paradigm shift not only accelerates workflows but also ensures that critical decision-making remains firmly in the hands of research teams.

Conclusion

In a world where operational efficiency is paramount, Florence stands out as a trailblazer in clinical research automation. With its innovative tools and visionary leadership, the company is making remarkable strides toward transforming the clinical trial landscape, ensuring that both sponsors and sites can work more harmoniously than ever before.